#32: Heart-Tracking Airpods, Robo-Sperm, and Needle-Free Chemo

• 🩸 Last week, it was Fastball’s brainwave test; now, a blood test developed by American and Swedish researchers. can flag Alzheimer’s biomarker proteins in minutes. (TOI)

• 🤖 Meet robo-sperm! Dutch scientists created steerable sperm bots coated with magnetic nanoparticles that zip through the womb like drones to boost IVF. (Independent)

• 🫁 GE HealthCare’s low-field MRI is making lung checks easy as a breeze. Quick, radiation-free and clinic-friendly for spotting asthma and more. (EH)

• ⌚️ Track, sweat and stay healthy- Apple’s got your back! The new AirPods Pro 3 monitors your heart rate, while the Watch Series drops smart alerts for hypertension, sleep scores and even ovulation estimates. (MobiHealth)

• 🤰🏻 Too many CT scans before pregnancy? They may raise miscarriage and birth defect risks. Odds of loss rose 8% with one, 14% with two and 19% with over three scans. (Reuters)

• 🦵🏻 Lab-made cartilage with a brain! This artificial cartilage implant senses joint stress and delivers arthritis-fighting drugs on the spot for precise relief. (TOI) 

• 🧠 Turn down pain like a playlist, U.S. scientists are experimenting with brain stimulation that switches off chronic pain. No meds or opioids needed. (CNN)

• 🫀 Goodbye rejection! Stem cells and gene-edited pigs could give longer-lasting, safer transplants, maybe even helping us chase that 150-year dream Xi and Putin joked about!  (BBC)

• 🚨 FDA greenlights J&J’s Inlexzo for bladder cancer. No surgery or standard chemo, just a tiny device that delivers chemo straight into the bladder for weeks at a time. (Reuters)

🇮🇳 India

• 🤱🏻 Hyderabad tops India’s breast cancer charts. Sedentary lifestyle, obesity, high alcohol intake, delayed motherhood, and lack of breastfeeding are tipping the scales. (ETHealth)

• 🦟 Game on, Malaria! ICMR licenses homegrown vaccine, AdFalciVax, to 5 pharma giants. Affordable and room-temperature stable, it blocks infection and transmission, fueling India’s push to eliminate malaria by 2030. (BS)

• ✨ India is set to roll out a mega health push for women & kids with 75,000 camps, nutrition drives and a nationwide wellness boost starting this Sept 17. Goal: healthier moms & kids. (ETHealth)

• 🗣️ India’s drug regulator wants medicines to ‘talk’. With QR codes for voice assistance to read the name and expiry date, and Braille labels to aid the visually impaired. (Livemint)

🌏️ Global

• 💉 When a “Hollywood drug” becomes an essential medicine: Semaglutide’s new WHO “Essential Medicines” status could redefine obesity and diabetes care worldwide. But can global health systems protect it from being misused? (BS)

• 🚬 Spain’s saying adiós to smoke clouds. From beaches to bus stops, it’s banning cigarettes, vapes and even herbal puffs to shield people from second-hand smoke. (TOI)

• 🍕 Pizza, fries, repeat! For the first time in history, childhood obesity has surpassed undernutrition. Today, 188M children and teens are obese (1 in 10), triple the rate since 2000. (Reuters)

🇮🇳 India

• 💰 AstraZeneca pumps ₹176 Cr into Chennai’s tech hub, supercharging AI, machine learning and next-gen healthcare. It’s the third India bet since June’25. (MedicalDialogues)

• 💲 Dr. Reddy scoops up Stugeron (anti-vertigo med) from J&J for ~$50.5M, boosting its Central Nervous System portfolio. (ET)

• 💥 Private equity giants are chasing Romsons Group, the Indian med-tech maker of syringes and catheters, eyeing a ₹1,200 Cr stake. (ETHealth)

• 📈 Apollo Hospitals is buying out International Finance Corporation’s 31% stake in Apollo Health & Lifestyle Ltd for ₹1,254 crore, taking near-total control of its retail healthcare arm. (ETHealth)

🌏️ Global

• 💸 Novartis to acquire U.S. based biotech company Tourmaline Bio for $1.4B, gaining a Phase III-ready anti-inflammatory therapy to strengthen its cardiovascular disease portfolio. (Reuters)

• 📈 U.S pharma giant AbbVie’s Rinvoq, a drug for autoimmune conditions like rheumatoid arthritis, locks exclusivity till 2037. Blocking generics and driving its $6B+ sales even higher. (Reuters)

📢 Enjoyed this edition? Forward it to a friend or colleague who’d love to stay informed! They can subscribe here.